Investment Rating - The report maintains a "B" rating for the new materials sector, indicating a leading performance compared to the market [1]. Core Insights - The new materials sector has shown resilience, with the new materials index rising by 0.86%, outperforming the ChiNext index by 2.54% during the week [3]. - The vitamin sector is experiencing a price surge due to geopolitical tensions in the Middle East, particularly affecting the Hormuz Strait, which has led to increased costs across the petrochemical supply chain [5]. - Key vitamin products such as Vitamin A and E have seen significant price increases, with Vitamin A reaching 110,000 CNY/ton (up 15.79% week-on-week) and Vitamin E at 101,000 CNY/ton (up 18.82% week-on-week) [5]. Summary by Sections Market Performance - The new materials sector has outperformed the broader market indices, with specific segments like battery chemicals rising by 10.69% and industrial gases by 1.78% [3][12]. - Over the past five trading days, the synthetic biology index fell by 0.92%, while semiconductor materials dropped by 2.80% [3][16]. Price Tracking - Amino acids have shown stable prices, with valine at 14,550 CNY/ton and arginine at 23,250 CNY/ton [4]. - The price of Vitamin A has increased significantly, reflecting a broader trend of rising prices in the vitamin sector due to supply constraints [4][5]. Investment Recommendations - The report suggests focusing on companies within the vitamin supply chain, such as New Hope Liuhe, Andis, Meihua Biological, and Zhejiang Medicine, as they are expected to benefit from the ongoing price increases [5][6].

Investment Rating - The report maintains a "B" rating for the new materials sector, indicating a leading performance compared to the market [1]. Core Insights - The new materials sector has shown resilience, with the new materials index rising by 0.86%, outperforming the ChiNext index by 2.54% during the week [3]. - The vitamin sector is experiencing a price surge due to geopolitical tensions in the Middle East, particularly affecting the Hormuz Strait, which has led to increased costs across the petrochemical supply chain [5]. - Key vitamin products such as Vitamin A and E have seen significant price increases, with Vitamin A reaching 110,000 CNY/ton (up 15.79% week-on-week) and Vitamin E at 101,000 CNY/ton (up 18.82% week-on-week) [5]. Summary by Sections Market Performance - The new materials sector has outperformed the broader market indices, with specific segments like battery chemicals rising by 10.69% and industrial gases by 1.78% [3][12]. - Over the past five trading days, the synthetic biology index fell by 0.92%, while semiconductor materials dropped by 2.80% [3][16]. Price Tracking - Amino acids have shown stable prices, with valine at 14,550 CNY/ton and arginine at 23,250 CNY/ton [4]. - The price of Vitamin A has increased significantly, reflecting a broader trend of rising prices in the vitamin sector due to supply constraints [4][5]. Investment Recommendations - The report suggests focusing on companies within the vitamin supply chain, such as New Hope Liuhe, Andisoo, Meihua Biological, and Zhejiang Medicine, as they are expected to benefit from the ongoing price increases [5][6].

Group 1 - The core reason for the strengthening of the US dollar since March is the relatively smaller impact on the US economy amid the Middle East conflict, leading to a return of funds to dollar assets, but this is not indicative of a liquidity crisis [1] - The narrative of a "weak dollar" has ended, reversing the previous trend of funds flowing from dollar assets to physical and other financial assets due to the US-Iran conflict [1] - Recent trends indicate that the strength of the US dollar may be nearing its end, with a potential confirmation of price bottoms for physical and non-US assets [1] Group 2 - Since late February, the vitamin market in Europe and domestically has experienced significant price volatility due to escalating Middle East conflicts and energy cost pressures, with Vitamin A prices increasing by nearly 82% and Vitamin E by over 75% [2] - The pharmaceutical team at Zhongyou Securities notes that the market space for related products may see effective recovery due to the combination of reversed supply-demand dynamics and geopolitical catalysts [2] - The raw material drug sector is currently driven by a dual momentum of "fundamental turning point + price increase expectations," with limited new capital expenditure in the past three years and a significant recovery potential for specific products like sartans and statins [3]

Industry Investment Rating - The industry investment rating is maintained at "Outperform" [2] Core Viewpoints - The basic chemical industry index closed at 4770.63 points, up 2.31% from last week, outperforming the CSI 300 index by 3.73% [18][19] - Among the 20 sub-industries, 15 saw gains, with the highest increases in other chemical raw materials (5.94%), civil explosives (4.50%), carbon black (4.33%), polyurethane (3.55%), and nitrogen fertilizer (2.95%) [19] - The geopolitical situation, particularly the conflict involving Iran, is reshaping cost curves and driving a continued price increase across all chemical products [6][8] Summary by Relevant Sections 1. Weekly Chemical Sector Review - The basic chemical industry index rose to 4770.63 points, marking a 2.31% increase, outperforming the CSI 300 index by 3.73% [18][19] - 20 sub-industries reported gains, while 5 experienced declines, with notable increases in other chemical raw materials and civil explosives [19] 2. Key Chemical Sub-Industry Tracking - **Polyester Filament**: Market prices have declined due to fluctuating oil prices, with average prices for POY, FDY, and DTY dropping [28][29] - **Tires**: The industry operating rates increased, with raw material prices showing slight upward trends [39][40] - **Refrigerants**: The R22 market remains stable, with supply and demand dynamics affecting pricing [47] 3. Chemical Product Price Trends - Among 380 tracked chemical products, 203 saw price increases, with notable rises in vitamin B5 calcium pantothenate (98%), liquid methionine, and diethylene glycol [25][26] - The top ten products with price increases include vitamin B5 calcium pantothenate, liquid methionine, and diethylene glycol, with significant percentage increases [26] - Conversely, products like tryptophan and TDI experienced notable price declines [27]

Summary of Conference Call Notes Industry Overview - The report focuses on the pharmaceutical raw materials and nitrile gloves industries, highlighting pricing trends and supply chain dynamics [1][2]. Key Points on Pharmaceutical Raw Materials - The raw material supply side entered a capacity digestion phase in 2023, with no new marginal changes expected after 2025, leading to a slow price transmission trend in the industry [1]. - Downstream customer inventories are at historical lows, driven by a "buy high, sell low" mentality, which is expected to trigger a replenishment cycle, ensuring the sustainability of price increases [1][3]. - Significant price increases have been observed in antibiotics like 6-APA and petroleum-related products (calcium pantothenate, vitamin E), with price turning points for sartans expected in the second half of 2026 [1][5]. - The raw material pharmaceutical companies are expected to maintain stable gross margins due to the presence of low-cost inventory and the long supply chain, which mitigates the impact of upstream cost increases [3][4]. Investment Recommendations in Pharmaceutical Raw Materials - Companies with a high proportion of raw material pharmaceuticals, such as Prologis and Tianyu Co., are recommended for their potential profit elasticity during this price increase cycle [1][5]. Key Points on Nitrile Gloves Industry - The nitrile gloves industry is expected to see significant profit elasticity starting in Q2 2026, driven by rising raw material prices, particularly butadiene and nitrile latex [1][6]. - The supply is concentrating among leading companies as smaller manufacturers face cost pressures and may cease operations, while leading firms benefit from long-term supply agreements [7][8]. - The demand for nitrile gloves remains rigid, especially in the medical sector, which accounts for over 60% of usage, and distributors are likely to increase stockpiling in response to rising prices [7][8]. Price Trends and Supply Chain Dynamics in Nitrile Gloves - The price of nitrile latex, which constitutes about 63% of production costs, has surged from over 5,000 RMB per ton to over 9,000 RMB per ton since late February 2026, with butadiene prices also experiencing a significant increase [8]. - The price transmission from raw materials to finished nitrile gloves is expected to exceed the increase in raw material prices, indicating a strong upward trend in final product pricing [8][10]. Global Market Dynamics for Nitrile Gloves - The global demand for disposable gloves is stabilizing after a period of rapid growth during the pandemic, with a projected steady growth rate in the coming years [9]. - Over 90% of global production capacity is concentrated in China and Malaysia, with leading domestic companies like YK Medical and Blue Sail Medical expected to increase their market share due to lower production costs compared to Malaysian competitors [9]. Future Trends and Strategic Moves - The export prices of nitrile gloves are at historical lows due to tariffs affecting the U.S. market, but an increase in raw material prices is expected to lead to significant price hikes in the near future [10][11]. - The establishment of overseas production bases in Southeast Asia is crucial for restoring and expanding market share in the U.S., with companies like YK Medical and Zhonghong Medical accelerating their investments in this region [11]. Key Indicators for Investors - Investors should monitor the following indicators: 1. Changes in upstream raw material prices, particularly nitrile latex and butadiene [12]. 2. Order price adjustments by leading companies in both domestic and U.S. markets [12]. 3. Inventory levels and stockpiling trends among distributors [12]. 4. Progress in domestic and foreign companies' expansion in Southeast Asia [12].

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform" [1] Core Insights - The vitamin industry has entered a new price increase cycle, with significant price rises for several core products from historical lows. As of March 20, 2026, the price of Vitamin E (VE) increased from 55.5 CNY/kg to 85.0 CNY/kg, a rise of 53.15%; Vitamin A (VA) rose from 63.0 CNY/kg to 95.0 CNY/kg, an increase of 50.79%; Vitamin B3 (VB3) and calcium pantothenate also saw increases of 40.58% and 13.50% respectively. This price increase is supported by supply constraints and rising raw material costs due to geopolitical factors [4][6][13]. Summary by Sections 1. High Concentration of Vitamin Supply and Rigid Demand - The demand for vitamins, particularly from the feed sector, is rigid and insensitive to price changes, as vitamins are considered essential and irreplaceable additives in feed. The cost of vitamins in feed is very low, accounting for only 0.51% in egg-laying hen feed and 0.15% in fattening pig feed, which allows for greater price elasticity [5][20][21]. - The supply of core vitamin products is highly concentrated among a few leading companies, which possess strong pricing power. For instance, the top three companies in the Vitamin A (VA) market control over 50% of the capacity, while calcium pantothenate production is dominated by a few firms with over 70% market share [5][24][23]. 2. Synthesis Pathways: Dominated by Chemical Synthesis - Vitamin E is primarily produced through chemical synthesis, with key intermediates being isophytol and 2,3,5-trimethylhydroquinone. The production process faces challenges related to the supply and price volatility of these intermediates [29][31]. - Vitamin A synthesis involves multiple pathways, with citral being a core intermediate. The production methods are complex and closely tied to the availability and pricing of citral, which has historically influenced Vitamin A prices [34][39]. 3. Historical Price Review: Supply Constraints as Core Drivers - Historical analysis shows that price increases in vitamins are primarily driven by supply constraints, often due to unexpected events such as factory accidents or environmental inspections. The high concentration of the industry amplifies price elasticity, allowing leading companies to exert significant pricing power [44][46]. - The demand for vitamins remains robust even during price increases, as customers tend to stock up in anticipation of further price hikes, demonstrating the significant price elasticity of vitamins [44][45].

Summary of the Conference Call on Vitamin Industry Industry Overview - The calcium pantothenate industry is experiencing severe overcapacity, with global production capacity at 50,000-60,000 tons compared to a demand of 23,000-25,000 tons. Major producers Newfa and Yifan have a combined capacity of 22,000 tons, sufficient to meet global demand [2][3] - The supply chain is heavily concentrated in China, with over 80% of global capacity located there [3] Key Points on Pricing and Market Dynamics - Calcium pantothenate prices fell to a historical low of 35 CNY/kg, driven by a 50% increase in raw material costs due to geopolitical tensions. Manufacturers have stopped quoting prices, leading to speculation of a price rebound [2][4][5] - The price recovery ceiling is estimated at 100 CNY/kg, constrained by the weak financial state of the downstream livestock industry, which is currently facing significant losses [2][4][7] - The recovery threshold for second and third-tier manufacturers to resume production is projected to be between 65-70 CNY/kg, as many small producers are currently unprofitable [2][7] Supply and Demand Insights - The global demand for calcium pantothenate is expected to reach approximately 23,000 tons by 2025, with major foreign producers like BASF and DSM contributing around 4,000-5,000 tons [3] - The top domestic producers, Newfa and Yifan, have capacities of 12,000 tons and 10,000 tons, respectively, with additional capacities under construction [3] Historical Context and Future Projections - Historical price surges have been linked to supply disruptions, such as safety incidents and environmental regulations. The current price increase is primarily driven by rising raw material costs and market speculation [6][10] - The market is currently in a state of negotiation between manufacturers and distributors, with a significant focus on the livestock industry's ability to absorb price increases [8][9][12] Other Vitamins Market Dynamics - Vitamin E and A are also under pressure, with Vitamin E's global capacity at 150,000 tons against a demand of 90,000 tons. The entry of new capacities from Wanhua Chemical is expected to impact the market significantly [2][14] - The price of Vitamin A has recently increased from 57 CNY/kg to over 75 CNY/kg due to supply constraints and market speculation [16] Conclusion - The calcium pantothenate market is characterized by overcapacity and fluctuating prices influenced by raw material costs and the financial health of the livestock sector. The interplay between supply and demand, along with geopolitical factors, will continue to shape the market dynamics in the near future [2][10][12]

Investment Rating - The report maintains an "Optimistic" rating for the chemical industry [2][3]. Core Insights - The report highlights that geopolitical conflicts have led to a significant increase in oil prices, with Brent crude reaching $93 per barrel as of March 6, 2026. If the Strait remains blocked for 4-6 weeks, prices may rise above $120, impacting the chemical sector positively in the short term [2][3]. - The report indicates that the chemical sector is experiencing upward price trends for MDI, TDI, and methionine due to increased costs and supply constraints, suggesting a potential price surge in the pesticide sector as well [2][3]. - The report emphasizes the importance of focusing on key materials for growth, particularly in semiconductor materials and packaging materials, as well as the impact of "anti-involution" policies accelerating the exit of outdated capacities [2][3]. Summary by Sections Macro Economic Analysis - Oil prices have surged due to geopolitical tensions, with Brent crude at $93 per barrel. If the situation persists, prices could exceed $120, which would have significant implications for the chemical industry [3][4]. - Coal prices are stabilizing, and natural gas prices are expected to decline as the U.S. accelerates its export facilities [3]. Chemical Sector Dynamics - The report notes that MDI and TDI prices are rising due to sustained cost pressures and supply constraints, with domestic companies controlling shipment volumes [2][3]. - The methionine market is expected to recover, with prices increasing to 22.5 yuan/kg, driven by geopolitical disruptions affecting supply [2][3]. Investment Recommendations - The report suggests focusing on various chains, including textile, agricultural chemicals, and export-related sectors, with specific companies highlighted for potential investment [2][3]. - Key companies to watch include Wanhua Chemical, Cangzhou Dahua, and others in the agricultural sector like Yangnong Chemical and Runfeng Co., which are expected to benefit from rising prices [2][3]. Company Valuation Insights - The report provides a valuation table for key companies, indicating their market capitalization and projected earnings, with specific recommendations for buy, hold, or sell based on their performance [14][15].

Group 1: Industry Performance - The chemical raw materials index increased by 6.24%, and the chemical machinery index rose by 3.49%, while the chemical pharmaceuticals index decreased by 1.54% and the pesticide and fertilizer index increased by 8.32% [1] - In the oil sector, the oil processing index rose by 6.74%, the oil extraction index increased by 1.77%, and the oil trading index went up by 5.97% [1] Group 2: Oil Prices - International crude oil prices showed an upward trend, with the NYMEX West Texas Intermediate crude oil futures closing at $61.07 per barrel, up 2.74% from January 16, and the ICE Brent crude oil futures closing at $65.88 per barrel, up 2.73% from January 16 [1] Group 3: Petrochemical Products - The top five petrochemical products with the highest price increases were battery-grade lithium carbonate (up 17.62%), industrial-grade lithium carbonate (up 10.24%), niacinamide (up 8.96%), styrene (up 7.96%), and tetrachloroethylene (up 7.86%) [1] - The top five petrochemical products with the largest price decreases were propylene oxide (down 6.15%), soft foam polyether (down 3.10%), dimethyl ether (down 2.67%), calcium pantothenate (down 2.63%), and POP-type polyether (down 2.59%) [1] Group 4: Capital Market Performance - The top five listed chemical companies with the highest stock price increases were Jianghua Micro (up 46.41%), Jiangtian Chemical (up 38.09%), Runbei Hangke (up 33.40%), Intercontinental Oil and Gas (up 30.95%), and Jiuding New Materials (up 28.47%) [2] - The top five listed chemical companies with the largest stock price decreases were Bofei Electric (down 24.16%), Shenjian Co. (down 15.12%), *ST Yatai (down 9.47%), Shanghai Xinyang (down 6.66%), and Baomo Co. (down 6.33%) [2]

Core Viewpoint - The company has been undergoing a business transformation and facing continuous declines in the price of calcium carbonate, leading to a history of performance downgrades for long-term investors. However, there are positive developments with significant sales growth in innovative drugs such as 627, Yinikang, and Xiluoda, raising questions about the potential for a performance increase in the 2025 annual report [1]. Group 1 - The company has been in a phase of business transformation and has experienced ongoing declines in calcium carbonate prices [1]. - Long-term investors have consistently received news of performance downgrades [1]. - The company announced significant sales growth for innovative drugs, which may impact future performance [1]. Group 2 - The company indicated that specific performance details will be available in the 2025 annual report, scheduled for disclosure on April 24, 2026 [1]. - Investors are encouraged to monitor company announcements for updates [1].